Key result
1-3 months of DAPT reduces major bleeding without increasing ischemic events in HBR patients post-PCI.
Why the study?
To review the clinical outcomes of different antithrombotic strategies in patients with high bleeding risk after percutaneous coronary intervention.
Do shorter durations of DAPT or de-escalation strategies decrease bleeding risk without increasing ischemic events in patients with high bleeding risk after PCI?
Population
Patients with high bleeding risk after PCI
Comparison
Different antithrombotic strategies
Design
Review
Authors
Loading...
Supports shorter DAPT in high-bleeding-risk post-PCI patients; leaves open need for dedicated RCTs to confirm safety.
Do shorter durations of DAPT or de-escalation strategies decrease bleeding risk without increasing ischemic events in patients with high bleeding risk after PCI?
Shorter durations of DAPT (1-3 months) or de-escalation strategies are effective in reducing major bleeding without increasing ischemic risk in high bleeding risk patients after PCI.
Almarzooq et al. (2023) conducted a review in High bleeding risk after percutaneous coronary intervention. Shorter durations of dual antiplatelet therapy (1-3 months) or de-escalation vs. Standard/longer duration DAPT was evaluated on Major bleeding and adverse ischemic events. Shorter durations of dual antiplatelet therapy (1-3 months) decrease the risk of major bleeding without increasing adverse ischemic events in patients with high bleeding risk after PCI.